Skip to main content
OpenTrials
Completed

NCT Number: NCT07554170

Comparison of Single-syringe vs. Double-syringe Techniques for Adenosine Administration in PSVT

The purpose of the study is to compare the effectiveness of two different methods of administering adenosine for the treatment of stable supraventricular tachycardia (SVT).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Supraventricular Tachycardia Arrhythmias, Cardiac Cardiac Conduction System Disease Cardiovascular Diseases Heart Diseases PSVT Pathologic Processes Pathological Conditions, Signs and Symptoms SVT Supraventricular Arrhythmia Supraventricular Tachycardias Tachycardia Tachycardia, Supraventricular

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Shahid Mohammadi Hospital, Bandar Abbas, Hormozgan, Iran

Loading trial locations.

About this study

The American Heart Association 2015 guidelines recommend adenosine for non-hypotensive patients with regular narrow complex SVT. Adenosine is usually given as a rapid intravenous bolus of 6mg over 1-2 seconds, followed by a 20ml saline flush. If the first dose does not result in the termination of SVT to normal sinus rhythm (NSR) within 1-2 minutes, a repeat dose of 12mg can be given, and the dose may be repeated one more time, if necessary, for a total of three doses.

The double-syringe technique (DST) is the standard method for administering adenosine. However, recent studies suggest that the single-syringe technique (SST) may be simpler and potentially beneficial. This technique injects adenosine and saline simultaneously at the same time instead of two separate injections. The study aims to determine if the SST method is non-inferior to the DST method.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 to 80 years
  • Presentation to the emergency department with narrow-QRS tachyarrhythmia
  • Heart rate ≥150 beats/min
  • No visible P wave or presence of retrograde P wave on ECG
  • Not responsive to Valsalva maneuvers lasting 15 to 30 seconds
  • Requiring adenosine administration

Exclusion criteria

  • Wide-QRS tachycardia or irregular R-R interval on ECG
  • Known allergy or contraindication to adenosine
  • Recent ingestion of dipyridamole, carbamazepine, or theophylline
  • Caffeine ingestion within the previous 2 hours

Treatment and study plan

Single-syringe Adenosine

Drug

Simplified method, containing both 6 mg of adenosine and 18 mL NS. If SVT termination failed: Second dose of adenosine with SS containing both 12 mg of adenosine and 18 mL NS. A total of three doses could be provided to each patient

Double Syringe Adenosine

Drug

One Syringe containing 6 mg of adenosine + one syringe containing 20 mL NS aided with a stopcock. If SVT termination failed: Second dose of adenosine (12 mg) + one syringe containing 20 mL NS. A total of three doses could be provided to each

Primary outcomes

  1. First-dose successful termination of PSVT

    Time frame: Within 2 minutes after administration of the first dose of adenosine.

    Proportion of participants with conversion from paroxysmal supraventricular tachycardia to sinus rhythm after the first dose of adenosine.

Secondary outcomes

  1. Total administered dose of adenosine.

    Time frame: From administration of the first dose until successful termination of PSVT or up to 10 minutes, whichever occurs first.

    Total cumulative dose of adenosine (mg) administered to achieve termination of PSVT.

Sponsors and collaborators

Lead sponsor

Hormozgan University of Medical Sciences

Other

Registry information

Official study title

Comparison of Single-syringe vs. Double-syringe Techniques for Adenosine Administration in Supraventricular Tachycardia: A Randomized Clinical Trial

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Apr 28, 2026
Registry last updated
Apr 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.